Editor's note channel feed

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW
Subscribe to Endpoints News

Cheers! End­points News turns 1 to­day — and we're un­wrap­ping in­fo on a new sub­scrip­tion plan

To­day, End­points News is one year old. Like any thriv­ing in­fant, we’ve been grow­ing at a fast pace, out­grow­ing a hasti­ly craft­ed chris­ten­ing gar­ment.

Start­ing from scratch, with just so­cial me­dia and a lot of word of mouth to re­ly on, web traf­fic to End­points was less than 14,000 vis­its per week. To­day we notch 14,000 per day, with a to­tal of 139,000 unique read­ers com­ing to the web­site in May.

Email sub­scrip­tions — the most im­por­tant met­ric we track — grew from zilch to 16,000 dai­ly bio­phar­ma sub­scribers drawn to our in­de­pen­dent style of jour­nal­ism. This was a re­sult of or­gan­ic, word-of-mouth ad­vo­ca­cy from our biggest fans. End­points’ “open rate”, the per­cent­age of read­ers who ac­tu­al­ly open and read the email re­ports, has nev­er fall­en be­low 40% — far above in­dus­try av­er­ages and more than dou­ble the rate you see at sim­i­lar pub­li­ca­tions.

The 10 most pop­u­lar re­ports in End­points News — so far

A lit­tle more than 5 months ago, Ar­salan Arif and I launched the main edi­tion of End­points News. We hit the ground run­ning and gun­ning for a dai­ly in­dus­try re­port that would pro­vide some re­al in­sights on the deals, da­ta and dra­ma flow­ing around the bio­phar­ma world every day.

We’re all about the lat­est news in con­text, guid­ed by 13+ years of dai­ly cov­er­age. And we re­cent­ly passed is­sue #100, with about a quar­ter mil­lion words of search­able con­tent.

What is End­points?

Let me start by out­lin­ing a few things we’re not do­ing.

We’re not an­oth­er ag­gre­ga­tion ma­chine. There are plen­ty of places that will give you a quick and ster­ile snap­shot of the bio­phar­ma R&D world. And that’s not us.

We’re not the AP or any oth­er wire ser­vice. There’s al­ready an AP, Reuters, Bloomberg, and they do a fine job. That job is cov­ered.

We’re not stock pick­ers. Frankly, we wouldn’t know where to be­gin.